Lupus

Twelve years is a long time by most measures, but in a field has rapidly changing as lupus nephritis research, it may as well be an eternity.

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and disease flares, according to a study.

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in Lupus Science & Medicine.

Exposure to various air pollutants, such as PM2.5 and nitrogen oxides, increases the risk for several autoimmune diseases, including psoriasis, lupus and rheumatoid arthritis, according to data published in Scientific Reports.

Requiring erythema alone for entry into cutaneous lupus erythematosus trials may exclude patients with skin of color and increase health disparities, according to a study.

Patients with cutaneous lupus erythematosus may be at an increased risk for atherosclerotic cardiovascular disease, even more than those with psoriasis, according to a study.

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.

After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor T-cell therapies for autoimmune rheumatic diseases.

WASHINGTON — A drug combining elsubrutinib with upadacitinib led to lower disease activity for up to 104 weeks in patients with moderately to severely active systemic lupus erythematosus, according to data presented at ACR Convergence 2024.